ALOX5: Polyunsaturated fatty acid 5-lipoxygenase
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Catalyzes the oxygenation of arachidonate ((5Z,8Z,11Z,14Z)- eicosatetraenoate) to 5-hydroperoxyeicosatetraenoate (5-HPETE) followed by the dehydration to 5,6- epoxyeicosatetraenoate (Leukotriene A4/LTA4), the first two steps in the biosynthesis of leukotrienes, which are potent mediators of inflammation.
- Drugs that act on it: 8
- Approved: 6
- In phases 1 to 3: 2
- Sponsors: 5
Who Is On It, and How Far Along
Every drug ChEMBL records acting on ALOX5, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
Approved6
Phase 30
Phase 22
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Pfizer225%
- Viatris225%
- Bausch Health113%
- Chiesi Group113%
- Tallikut Pharmaceuticals, Inc.113%
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule8100%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Arachidonate 5-lipoxygenase inhibitor.| Mesalamine | Approved | Viatris | Small molecule | Inhibitor | — | 28 | — |
| Sulfasalazine | Approved | Pfizer | Small molecule | Inhibitor | — | 19 | — |
| Meclofenamic acid | Approved | — | Small molecule | Inhibitor | — | 2 | Boxed warning |
| Zileuton | Approved | Chiesi Group | Small molecule | Inhibitor | — | 1 | — |
| Balsalazide | Approved | Bausch Health | Small molecule | Inhibitor | — | 0 | — |
| Olsalazine | Approved | Viatris | Small molecule | Inhibitor | — | 0 | — |
| Atreleuton | Phase 2 | Tallikut Pharmaceuticals, Inc. | Small molecule | Inhibitor | — | 0 | — |
| PF-4191834 | Phase 2 | Pfizer | Small molecule | Inhibitor | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 19 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Asthma
- 0.58
- Proctitis
- 0.50
- Arthralgia
- 0.46
- Osteoarthritis
- 0.38
- Crohn disease
- 0.38
- Arthritic joint disease
- 0.37
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- ALOX5
- Related
- Arachidonate 5-lipoxygenase
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL215, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P09917, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets